与癌共舞

  • 患者服务: 与癌共舞小助手
  • 微信号: xzs60619

QQ登录

只需一步,快速开始

开启左侧

ARQ197试药讨论

  [复制链接]
65869 85 憨豆精神 发表于 2011-7-2 18:07:31 |
以德服人  大学四年级 发表于 2013-5-29 22:42:21 | 显示全部楼层
关注一下。。。。。

举报 使用道具

回复 支持 0 反对 1
bkcui  大学三年级 发表于 2013-6-6 11:36:19 | 显示全部楼层
ARQ197治疗肝癌III期临床研究方案。
这个报告总结了,2期临床结果,OS:7.2月VS 3.8月,开始了3期临床研究。入组人群为免疫组化法检测MET高表达的HCC,接受过包括索拉菲尼在内的系统治疗。计划入组303例患者,按照2:1随机分组,治疗方案:Tivantinib 240mg bid 或者安慰剂。研究终点为OS,次要终点为PSF。期待有好的结果。


Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).


Abstract:

Background: Tivantinibis a selective, non-ATP competitive, oral inhibitor of MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF). MET over-expression is associated with poor prognosis in HCC patients. A phase Ib study (Santoro et al, Br J Cancer, 2013) with tivantinib 360mg BID revealed no worsening of liver function in cirrhotic HCC pts. A randomized, placebo-controlled phase 2 study identified HCC patients with high tumor MET expression at immunohistochemistry (IHC) as the target population for tivantinib in second line (overall survival: 7.2 months on tivantinib, 3.8 months on placebo, HR: 0.38, p=0.01), and selected 240mg BID as the appropriate dose for HCC patients (Santoro et al, Lancet Oncol, 2013). Methods: Enrollment forthis phase III clinical trial (ARQ 197-A-U303, NCT01755767) has begun.Eligible pts must present with Child Pugh A; ECOG performance score <1; inoperable RECIST 1.1 measurable disease; adequate bone marrow, liver and kidney functions; no prior liver transplant. Pts must have progressed after or not tolerated one prior line of systemic therapy including sorafenib and their tumor samples must be deemed MET-High by IHC at a central laboratory to be eligible. Approximately 303 pts are randomized 2:1 to receive tivantinib 240mg PO twice daily or placebo. Pts are stratified by vascular invasion, metastases, and alphafetoprotein level, and they are evaluated by CT or MRI scan at 8-week intervals. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival and safety. Treatment continues until confirmed disease progression or unacceptable toxicity. Pts discontinued from study treatment will be followed for survival. Participating centers are located in Europe, Australia, New Zealand, and the Americas. This trial is expected to complete enrollment by mid-2015, and an interim analysis is planned when approximately 60% of OS events are reached. Clinical trial information: NCT01755767.

举报 使用道具

回复 支持 0 反对 1
老马  退休老干部 发表于 2013-6-18 01:33:33 | 显示全部楼层
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
http://cancerres.aacrjournals.org/content/73/10/3087.abstract
The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF). The HGF/c-MET axis is often dysregulated in tumors. c-MET activation can be caused by MET gene amplification, activating mutations, and auto- or paracrine mechanisms. Thus, c-MET inhibitors are under development as anticancer drugs. Tivantinib (ARQ 197) was reported as a small-molecule c-MET inhibitor and early clinical studies suggest antitumor activity. To assess whether the antitumor activity of tivantinib was due to inhibition of c-MET, we compared the activity of tivantinib with other c-MET inhibitors in both c-MET–addicted and nonaddicted cancer cells. As expected, other c-MET inhibitors, crizotinib and PHA-665752, suppressed the growth of c-MET-addicted cancers, but not the growth of cancers that are not addicted to c-MET. In contrast, tivantinib inhibited cell viability with similar potency in both c-MET-addicted and nonaddicted cells. These results suggest that tivantinib exhibits its antitumor activity in a manner independent of c-MET status. Tivantinib treatment induced a G2–M cell-cycle arrest in EBC1 cells similarly to vincristine treatment, whereas PHA-665752 or crizotinib treatment markedly induced G0–G1 cell-cycle arrest. To identify the additional molecular target of tivantinib, we conducted COMPARE analysis, an in silico screening of a database of drug sensitivities across 39 cancer cell lines (JFCR39), and identified microtubule as a target of tivantinib. Tivantinib-treated cells showed typical microtubule disruption similar to vincristine and inhibited microtubule assembly in vitro. These results suggest that tivantinib inhibits microtubule polymerization in addition to inhibiting c-MET. Cancer Res; 73(10); 3087–96. &copy;2013 AACR.

个人公众号:treeofhope

举报 使用道具

回复 支持 0 反对 1
uzhh  高中三年级 发表于 2013-7-7 23:09:39 | 显示全部楼层
联系了几个有arq197的厂家,都贵的很,说是很难合成。

举报 使用道具

回复 支持 0 反对 1
cgjrg  初中二年级 发表于 2013-10-19 21:20:22 | 显示全部楼层
关注中........

举报 使用道具

回复 支持 0 反对 1
无悔  大学四年级 发表于 2013-12-24 10:50:16 | 显示全部楼层
每月1684800元。。。。

点评

160几万。。。  发表于 2013-12-26 18:58

举报 使用道具

回复 支持 0 反对 1
dayanzi  大学一年级 发表于 2014-1-7 22:53:19 | 显示全部楼层
168万??真的吗?

举报 使用道具

回复 支持 0 反对 1
shany  大学二年级 发表于 2014-2-6 12:52:22 | 显示全部楼层
Tivantinib进行中的III期试验进展

ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib

Data Monitoring Committee approves continuation of Phase 3 METIV-HCC liver cancer trial following safety and pharmacokinetic analyses Asian partner Kyowa Hakko Kirin provides top-line data on ATTENTION trial in non-squamous non-small cell lung cancer

WOBURN, Mass., Jan 16, 2014 (BUSINESS WIRE) -- ArQule, Inc. ARQL -3.60%  today provided clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer) conducted by the Company and its partner, Daiichi Sankyo Co., Ltd., and on the completed amended Phase 3 ATTENTION trial in non-squamous non-small cell lung cancer (NSCLC) conducted in Asian territories by its partner, Kyowa Hakko Kirin Co., Ltd.

METIV-HCC Trial
III期肝细胞癌试验

The Data Monitoring Committee (DMC) of the METIV-HCC trial has recommended continuation of the ongoing pivotal Phase 3 METIV-HCC trial of tivantinib as a single agent in hepatocellular carcinoma with a lower dose of tivantinib, 120 milligrams (mg) tablets administered twice daily (BID). This decision followed the DMC’s review of data analyses from a predefined number of patients who received this lower dose.
数据监察委员会推荐继续试验,降低剂量为120mg每日两次。

Recently completed safety analyses among patients treated with 120 mg BID tivantinib tablets showed that the incidence of neutropenia was reduced with this lower dose. In addition, pharmacokinetic analyses from this patient cohort, reviewed by the DMC, demonstrated that the plasma exposure of the 120 mg BID tablets dose was comparable to the exposure achieved with the 240 mg BID capsules dose employed in the Phase 2 trial, with similar medians and overlapping ranges.
最近的分析显示120mg每日两次的较低剂量能降低中性粒减少的发生。药代动力学显示120mg与II期临床中使用的240mg剂量血浆暴露类似。

A dose reduction from 240 mg BID tablets to 120 mg tablets BID was implemented in September, 2013 following the observation of a higher incidence of neutropenia in the initial phase of the METIV-HCC trial than was observed in the Phase 2 trial in the same patient population where a 240 mg BID capsule dose was administered. Certain enhanced patient monitoring procedures had been temporarily instituted to confirm the safety profile of the lower dose.
剂量降低从2013年九月开始实施,此前发现中性粒减少的发生比在II期临床中观察到的要多。

The METIV-HCC trial is a pivotal randomized, double-blind study of tivantinib as single agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC. The primary endpoint is overall survival in the intent-to-treat population, and the secondary endpoint is progression free survival in the same population. METIV-HCC is being conducted under a Special Protocol Assessment (SPA).
METIV-HCC是一项关键性的双盲随机试验,研究tivantinib作为单药治疗曾经接受过治疗的MET高表达的肝细胞癌患者。主要终点是愿意治疗人群的总生存期,次要终点是无进展生存期。

举报 使用道具

回复 支持 0 反对 1
shany  大学二年级 发表于 2014-2-6 13:11:37 | 显示全部楼层
本帖最后由 shany 于 2014-2-6 13:15 编辑

继续上贴

ATTENTION Trial
非小细胞肺癌III期试验

Kyowa Hakko Kirin has provided the Company with top-line results of the amended Phase 3 ATTENTION clinical trial evaluating the combination of tivantinib (ARQ 197) and erlotinib in patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR (epidermal growth factor receptor) in Asia (Japan, Korea and Taiwan).
III期临床ATTENTION评估联合tivantinib和厄洛替尼在亚洲EGFR野生型晚期非鳞非小细胞癌患者中的疗效。

Enrollment in ATTENTION had been originally planned for 460 patients, and the trial’s statistical analysis plan was calibrated accordingly and remained unchanged. Recruitment of new patients was permanently suspended in October, 2012 based on a recommendation by the trial’s Safety Review Committee following an observed imbalance in interstitial lung disease (ILD) cases as a drug-related adverse event. Patients who received treatment in ATTENTION as of October, 2012 were allowed to continue thereafter in the trial after being re-consented, and including such patients, a total of 307 patients were included in the final analysis.
该实验原计划入组460名患者,但在2012年十月中止了入组计划,原因是安全评估委员会发现药物相关的间质性肺炎发生率不平衡。2012年十月以前开始治疗的患者在自愿的前提下被允许继续治疗,最终分析包括307名患者。

In the ITT population, overall survival (OS) favored the treatment arm of tivantinib plus erlotinib compared to the erlotinib only control arm, but it was not statistically significant (median OS of 12.9 months vs 11.2 months, hazard ratio = 0.89, p = 0.4). Progression free survival (PFS) and overall response rate (ORR) results also showed a numerical trend toward improvement favoring the treatment arm.
在愿意接受治疗的人群中,联合治疗组总生存期高于厄洛替尼单药组,但无统计显著差异(12.9个月对比11.2个月)。无进展生存期和总响应率也类似。

The safety profile observed in ATTENTION was in line with what had been previously observed in other NSCLC trials with tivantinib, with the exception of a reported imbalance in ILD, which is a known adverse event in Japanese patients treated with EGFR inhibitors such as erlotinib. In the Phase 3 MARQUEE trial in non-squamous NSCLC conducted in Western countries, no imbalance was observed in the incidence of ILD between treatment and control arms, with one case (0.2%) reported in the treatment arm and four cases (0.8%) in the control arm.
除外间质性肺炎,该实验观察到的安全性跟此前其他tivantinib用于非小细胞癌的试验一致。间质性肺炎对于接受EGFR抑制剂的日本患者来说是一个已知的副作用。在针对西方人群的非鳞非小细胞癌的III期试验MARQUEE中没有观察到治疗组和对照组之间间质性肺炎发生率的不平衡。

ATTENTION is a Phase 3 randomized, double-blind trial comparing OS of second or third line non-squamous NSCLC patients with wild-type EGFR treated with tivantinib and erlotinib to OS of patients treated with placebo and erlotinib. Complete data from this study, including biomarker analyses, are expected to be presented at a future scientific meeting.

举报 使用道具

回复 支持 0 反对 1

发表回复

高级模式
B Color Image Link Quote Code Smilies

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
改版要求
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表